One of the unresolved questions in medical immunology is the inter-relation of inflammation, the immune response, and disease. The debate over the role of inflammation in disease dates back the mid-nineteenth century. Our research examines one of the central questions of this debate - the host response to cell injury.

TherimuneX's technology is a drug discovery platform that relates to a new family of endogenous lipopeptides and their immune regulating properties. Induced in response to cell injury, these peptides activate the innate arm of the immune response. This discovery has enabled us to directly relate cell injury to the pro-inflammatory immune cascade and formulate a model for the immunopathology underlying many human diseases.

Our discovery has lead to the development of a new therapeutic peptide for treating and preventing infectious diseases. We are also discovering new therapeutics and new biomarkers for use in the rheumatic diseases, autoimmune diseases, metastatic neoplastic diseases, and vascular diseases.